CEO Yu-Hsin Lin highlighted the completion of Phase III PHOENIX trial enrollment with 530 subjects for geographic atrophy and the completion of the Phase III DRAGON trial for Stargardt's disease, ...

CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz emphasized Bio-Rad's ...

Rachel King is a trailblazer in biotech, a venture capitalist turned co-founder and CEO, now turned industry leader. As CEO of the Biotechnology Innovation Organization (BIO), King has focused in ...

INmune Bio is working with the FDA to define a path forward for the therapy based on these results. According to the company, its cash position stood at approximately $27.7 million as of September 30, ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...